| A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT05254743) | Loxo Oncology, Inc. | 2022-07-22 |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT05362773) | MacroGenics | 2022-07-13 |
| Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma (NCT04648475) | Chongqing Precision Biotech Co., Ltd | 2020-08-25 |
| γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse (NCT04439721) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2020-05-01 |
| CAR-T Cells in the Treatment of Malignant Hematological Tumors (NCT05619861) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-04-27 |
| CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma (NCT04649983) | Chongqing Precision Biotech Co., Ltd | 2019-09-01 |
| CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma (NCT04271410) | Chongqing Precision Biotech Co., Ltd | 2019-06-01 |
| Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia (NCT03599375) | jiuwei cui | 2019-05-01 |
| Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma (NCT03605589) | Children's Hospital Medical Center, Cincinnati | 2018-09-27 |
| XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects (NCT03598179) | The First Affiliated Hospital with Nanjing Medical University | 2018-06-01 |
| CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. (NCT03614858) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2017-09-01 |
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. (NCT03229200) | Pharmacyclics Switzerland GmbH | 2017-05-22 |
| Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma (NCT02518750) | St. Jude Children's Research Hospital | 2016-11-23 |
| Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL (NCT02848911) | Affimed GmbH | 2016-10-01 |
| Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL (NCT03564470) | Nanfang Hospital, Southern Medical University | 2016-02-14 |
| A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia (NCT02672501) | Shanghai GeneChem Co., Ltd. | 2016-01-01 |
| Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies (NCT02813837) | Innovative Cellular Therapeutics Co., Ltd. | 2015-06-01 |